"Which begs the question,why do we have a scientist as our main announcement conduit? Scientist by training are understated and tentative. Surely we would be better served by someone skilled in the dark art of PR."
Glyn is a management consultant specialising in business development, organisational consulting and the restructuring of business operations. Major clients such as BHP, RIO Tinto and the Federal Government, have engaged the services of Glyn, so in my view he is suitably qualified in his official role as one of the directors, and when the time comes to advise the market of any material deal with a significant value to the price of our securities, I have every confidence that he will translate this information with crystal clarity.
In regards to the neglected price of our company's securities, which some have attributed to a lack of support shown by management, whilst the disclosure debate will no doubt continue, I think it's also important to appreciate that each one of our directors have also invested a considerable amount of their own funds into the company over the years, and they also supported the December 2009 rights issue, taking up over 8.3m shares @ 2.3c ps for a total value of almost $200k. At todays price that would've given them about 15.4m shares.
Additionally, the condition of director performance shares requires that the company have two commercialized products, one of the company's own design and development, and one partner product which incorporates OBJ technology, on the market within the next two years. In regards to expected timelines for the development and commercialisation of any pharmaceutical, healthcare, or cosmetic product which delivers an API through the skin, we must appreciate that two years under any given circumstances would be nothing short of a miracle, however we must also assume that the conditions set by management to meet those goals would have also allowed themselves ample time to achieve to them by.
From basic research, through discovery, pre-clinical development, PoC, human clinical trials, pre-market applications, and defining packaging and distribution channels, one would expect that we might be close to the finish line, or as certain job placement ads may state, leading into "the final development stages and managing the international roll-out..."
OBJ Price at posting:
1.2¢ Sentiment: LT Buy Disclosure: Held
(20min delay)